Study Shows Long-Term Efficacy of Ultrasound Renal Denervation for Hypertension

In the latest update on hypertension research, a 36-month durability study on ultrasound renal denervation (uRDN) for patients with resistant hypertension was conducted. The study, known as RADIANCE-HTN TRIO, aimed to assess the long-term efficacy of uRDN in patients who were resistant to combination therapy.

The primary findings of the study revealed that uRDN led to a significant reduction in blood pressure over the 36-month period. Patients who underwent uRDN showed a sustained decrease in office blood pressure measurements, indicating the durability of the treatment. The study included patients with resistant hypertension who were unresponsive to multiple anti-hypertensive medications.

The research methodology involved a randomized, sham-controlled trial where patients were either assigned to undergo uRDN or a sham procedure. The results showed that the efficacy of uRDN persisted up to 36 months, with no safety concerns reported. Patients undergoing uRDN experienced a notable reduction in office blood pressure levels, suggesting a lasting benefit from the procedure.

The study also highlighted the importance of long-term follow-up in evaluating the effectiveness of uRDN in real-world clinical settings. Patients who received uRDN continued to show improvements in blood pressure control, even after being unblinded and receiving standard care medications as per their physicians’ recommendations.

Experts in the field emphasized the significance of these findings in understanding the role of uRDN in managing resistant hypertension. The study provided valuable insights into the sustained efficacy of uRDN over an extended period, demonstrating its potential as a treatment option for patients with challenging-to-treat hypertension.

Overall, the 36-month durability study of uRDN for resistant hypertension sheds light on the long-term benefits of this innovative treatment approach. The results underscore the importance of continued research and monitoring to optimize the management of hypertension and improve patient outcomes in the future.